Key facts
- Form Bio’s last known valuation is $116.3M (Dec 2024).
- It has raised $64.0M across 1 recorded rounds; the latest was Early Stage VC ($16.0M) in Sep 2022.
- Notable investors include Gaingels, Calm Ventures, Draper Associates, Breyer Capital, Builders VC — 17 tracked in total.
- Form Bio has filed 1 Form D with the SEC, most recently Sep 2022 ($16.0M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Form Bio
Funding rounds
1 roundsAbout Form Bio
Developer of artificial intelligence-powered tools designed to accelerate AAV gene therapy development through predictive and analytical capabilities at each stage, from candidate design to preclinical validation. The company's platform offers predictive modeling, automated candidate optimization, and virtual biomanufacturing, enabling researchers to advance therapeutic designs with efficiency and improved efficacy.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2022
- Employees
- 43
- Website
- formbio.com/
- Ownership
- Privately Held (backing)
Form Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Form Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Form Bio in its N-PORT filings yet. We sweep new filings monthly.